ReviewTaiwan journal of ophthalmology
Advancing optical coherence tomography angiography to the clinic.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Optical coherence tomography (OCT) angiography (OCTA) is a new clinical technology that advances the capabilities of OCT imaging by adding the ability to readily visualize vascular anatomy down to the capillary scale. With this level of detail, OCTA can be used to identify many important vascular pathologies such as capillary dropout, microaneurysms, or neovascularization. Because it offers high-resolution, high-contrast imaging of these and similar features, OCTA is useful not just for visualization but also for quantification. Quantification is a powerful feature that enables the potential for diagnostics, staging, evaluation of treatment response, and patient monitoring in a more rigorous way than simple observation. In this review, we will examine several OCTA measurements with either demonstrated clinical utility or clinical potential through the lens of three prevalent blinding diseases: diabetic retinopathy, age-related macular degeneration, and glaucoma. We will discuss the merits of these various measurements and care that should be taken in their interpretation and analyze their role in patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.